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Mammalian aging can be delayed with genetic, dietary, and pharmacologic approaches. Given
that the elderly population is dramatically increasing and that aging is the greatest risk factor
for a majority of chronic diseases driving both morbidity and mortality, it is critical to expand
geroscience research directed at extending human healthspan.The NIH mission is ‘‘to seek fundamental
knowledge about the nature and behavior
of living systems and the application
of that knowledge to enhance health,
lengthen life, and reduce illness and
disability.’’ NIH-funded research is struc-
tured to address the major diseases
driving morbidity and mortality. Interro-
gating and developing therapeutics for
one disease at a time has often been
productive. Will, however, the success of
this approach be sustainable for the
chronic aging diseases, such as neurode-
generative and metabolic syndromes,
most cancers, and cardiovascular dis-ease? Findings in the last few decades
have made it impossible to ignore the
integrative nature of human physiology.
Pathologies thought to be disparate are
now understood to be connected. This
awareness raises the possibility that the
stated goals in the NIH mission statement
are best achieved by novel integrated
approaches to health and disease, with
the understanding that biological systems
change with age.
Basic aging research has always been
intriguing but until recently seemed to
hold few concrete solutions to advance
health. Despite limited resources, the fieldCell 159,recently erupted and now offers routes
to achieve a new and ambitious goal—a
substantial extension in health life ex-
pectancy, or ‘‘healthspan.’’ The lynchpin
is that aging itself is the predominant
risk factor for most diseases and condi-
tions that limit healthspan. Moreover,
interventions that extend lifespan in
model organisms often delay or prevent
many chronic diseases. This knowledge
launched the era of geroscience, which
strives to understand how aging enables
chronic disease and seeks to develop
novel multi-disease preventative and
therapeutic approaches.November 6, 2014 ª2014 Elsevier Inc. 709
Figure 1. The Seven Pillars of AgingThe trans-NIH Geroscience Interest
Group (GSIG) held a recent summit where
the mechanistic relationships between
aging and chronic diseases were dis-
cussed. An executive session was tasked
with identifying strategies to: (1) develop a
systematic understanding of aging mech-
anisms; (2) elaborate mechanistic links
between aging and chronic disease; and
(3) recommend pathways to identify and
develop therapies or preventative ap-
proaches for age-associated diseases.
Here, we describe the summit’s con-
clusions, emphasizing the needs for a
concerted effort to understand the aging
process and to exploit this knowledge to
extend human healthspan.
The Pillars of Aging
Attempts to define the causes of aging
have been impeded by the complexity
of the phenotype coupled with the
costs and duration of longevity studies.
Recently, progress has accelerated,
bringing geroscience to the forefront.
First, invertebrate models have identified
conservedmolecular pathways impacting
aging. Second, mammalian studies have
generated a more detailed understanding
of age-associated pathologic changes.
Third, several interventions that extend
lifespan have been shown to also improve
aspects of healthspan—long-lived mu-
tants are often resistant to age-related
chronic diseases. Finally and urgently,
the global population is aging, with710 Cell 159, November 6, 2014 ª2014 Elsevlooming dire economic and societal im-
pacts. While life expectancy continues
to rise, healthspan is not keeping pace
because current disease treatment often
decreases mortality without preventing
or reversing the decline in overall health.
Elders are sick longer, often coping with
multiple chronic diseases simultaneously.
Thus, there is an urgent need to extend
healthspan.
Key themes emerged regarding pro-
cesses that promote aging, with recent
reviews describing overlapping sets of
five to ten processes processes (Lo´pez-
Otı´n et al., 2013; Mahmoudi and Brunet,
2012). Seven pillars were discussed at
this recent summit (Figure 1). Specific rec-
ommendations for each pillar emerged
(Table 1), but, more importantly, their
connectedness was striking. The themes
were not seven independent factors
driving aging; rather, they were highly
intertwined processes, and understand-
ing the interplay between these seven
pillars is critical.
An Aging Research Initiative
Collectively, chronic diseases comprise
the majority of global disease burden and
are the most common causes of mortality
(http://www.healthmetricsandevaluation.
org/tools/data-visualizations). Medical
research has historically targeted dis-
eases separately, assuming that organ
systems act independently. Yet, optimal
functionality for any single system re-ier Inc.quires overall organismal health, impelling
inquiries into the interdependence of
these relationships to develop multiscale
network models that incorporate the
physiologic changes accompanying ag-
ing. Targeting diseases individually for
an aging population is also complicated
because most elders have multiple
morbidities that interact, confounding
therapeutic strategies. By understanding
how aging enables pathology, new thera-
peutics will arise for multiple chronic
diseases, providing an opportunity to
extend human healthspan by targeting
aging directly. There is cause for opti-
mism; however, much must happen
to achieve this goal, including an infu-
sion of resources to accelerate research
and regulatory changes that pushmedical
care toward chronic disease prevention.
Here, we focus on a limited set of short-
and intermediate-term scientific goals
that will accelerate geroscience and will
launch novel approaches to reduce the
impact of the major global healthcare
burden: the chronic diseases of aging.
Merge Geroscience with Research
on Human Chronic Disease States
The mouse has emerged as a primary
mammalian model to understand aging
and disease. Although mice develop only
some pathologies approximating human
aging, other pathologies can be modeled
through transgenic or genome-editing
approaches. There are, however, con-
cerns about the validity of mouse models,
as preclinical studies often identify thera-
peutics that fail in humans. Given that
mouse studies provide much of the evi-
dence for delayed aging, pro-longevity
interventions that extend healthspan
may also not achieve human validation.
Yet, a key difference between aging
studies and many disease models is that
aging can be studied in normal mice or
other species; therefore, evolutionarily
conserved interventions can be identified
that cut across species.
Focus in three areas may improve
consistency between mice and humans.
First, mouse studies generally fail to use
aged mice—most human chronic dis-
eases rise with age, yet murine models
invoke pathology in young mice. Aging
creates a distinctive systemic milieu;
drugs that show efficacy in the young
may not work in the aged. Therefore,
aging should be incorporated into animal
Table 1. Critical Areas of Aging Research and Important Goals
Areas of Aging Research Important Goals
Adaptation to stress Bridge continuum from psychological to molecular stresses
Differentiate hormesis from toxic stress
Better align human and animal studies
Epigenetics Biomarker development: chronologic vs. biologic aging
Link age-related environmental inputs to epigenetic signatures
Test small molecules that regulate enzymes controlling epigenetic events
Inflammation Differentiate adaptive and maladaptive inflammatory responses
Define age-related inflammatory sources and their systemic effects
Determine how obesity and metabolic dysfunction alter inflammation with age
Macromolecular damage Generate systems-level understanding of the types of macromolecular damage
and their roles in chronic disease states
Understand how stochastic damage influences the variability of aging
Metabolism Define role of signal transduction pathways linked to metabolism in the aging process
Understand contribution of circadian clocks to aging and metabolism
Connect metabolic dysfunction with tissue-specific decline in aging
Proteostasis Identify proteostatic pathways that are overwhelmed in specific chronic disease states
Examine crosstalk between proteostasis machineries
Understand non-cell-autonomous signaling and activation of proteostasis pathways
Stem cells and
regeneration
Determine whether declining adult stem cell function drives aging and chronic disease
Examine how aging and associated disease impair adult stem cell function
Determine how macromolecular damage accumulates in aging adult stem cell poolschronic disease models, a recommen-
dation increasing time and cost but also
likely yielding results that will translate
more accurately to humans and will thus
provide long-term savings.
A second goal is to employ whenever
possible genetically outbred lines to intro-
duce natural population variation, better
mimicking human diversity. A third is
to incorporate mild stress into mouse
studies to more accurately reflect the
human condition. These stresses should
include low-level chronic stress, including
psychological sources. Many animal
studies use acute stresses that are not
experienced by humans. It will also be
essential to distinguish stresses that
induce a hormetic response, protecting
from later acute stress, from those uncon-
ditionally deleterious.
Though aging promotes disease, new
findings suggest the reciprocal may also
be true: diseases and/or their treatments
may accelerate aging pathologies. For
instance, long-term cytomegalovirus
(CMV) infection can induce chronic
inflammation and exhaust the adaptive
immune response, accelerating unrelated
age-associated pathologies (Pawelec
et al., 2012). This is also observed in
human immunodeficiency virus (HIV) pa-
tients, attributable either to virus-inducedinflammation or, ironically, treatment
modalities (Pathai et al., 2014). Similarly,
children subjected to chemotherapies
often present with accelerated aging
features decades later (Robison and Hud-
son, 2014). These findings highlight rela-
tionships between disease and aging,
calling for a thorough analysis in humans
and animal models.
Expand Interventions that Extend
Lifespan and Healthspan
Mammalian lifespan, and also health-
span, can bemodified by dietary, genetic,
and pharmacologic interventions. Several
drugs are reported to extend mouse
lifespan and healthspan (Kennedy and
Pennypacker, 2014), raising the possibil-
ity that human aging can be delayed.
Although obstacles exist, the repertoire
of aging interventions should be greatly
expanded. For instance, dietary restric-
tion is long known to extend rodent
lifespan, though not easily adapted to
humans. Understanding links between
diet and aging, as well as approaches
like intermittent fasting, may yield prac-
tical strategies. Moreover, given that
different mouse strains respond variably
to dietary restriction, it may be necessary
to design personalized diets optimizing
healthspan based on individual genetics
and lifestyle.Cell 159,The role of the microbiome in response
to diet and aging also requires elabo-
ration. Preliminary data suggest that the
gut microbiome change dramatically
with age (Heintz andMair, 2014), although
causes and effects remain undetermined.
This area is particularly important for
understanding obesity and metabolic
diseases. In addition, it should be deter-
mined whether altering the microbiome
offsets features of aging. Though early,
the therapeutic hurdles to altering the
gut microbiome may be more easily sur-
mountable than those using standard
pharmacology.
Exciting findings have demonstrated
that aging in rodents can be accelerated,
stalled, or reversed simply by altering
the systemic environment (Rando and
Wyss-Coray, 2014). These findings were
initially spotlighted by heterochronic
parabiosis experiments, in which the
circulation of old and young mice was
coupled. More recent findings from
multiple labs now indicate that hallmarks
of aging can be modulated by circulatory
factors, which are beginning to be identi-
fied. This growing line of inquiry may offer
tractable routes to extend healthspan.
Rapamycin was the first drug shown to
robustly extend mouse lifespan (Johnson
et al., 2013), a finding repeated in differentNovember 6, 2014 ª2014 Elsevier Inc. 711
backgrounds. It also increases health-
span in most studies and is protective
in many age-related disease models.
Other drugs, including metformin and
acarbose, also extend mouse lifespan
(Harrison et al., 2014; Martin-Montalvo
et al., 2013). Continued efforts should be
directed at identifying and optimizing
new molecules with these properties and
understanding those already identified
(Kennedy and Pennypacker, 2014). Ulti-
mately, drug combinations may be
optimal. Further, many aging drugs
approved for a single chronic disease
(e.g., metformin, rapamycin) may have
efficacy because they target basic as-
pects of aging. Therefore, a thorough
analysis of drugs clinically approved for
chronic diseases should be performed
to identify those with the potential to
increase healthspan.
Elaborate Environmental and
Stochastic Factors Driving Aging
Conserved longevity pathways have been
identified across disparate eukaryotic
species. However, aging also depends
on environmental factors, which may be
modifiable. Yet, the specific environ-
mental influences on aging, aside from
obvious culprits such as smoking and
obesity, remain poorly understood. More-
over, stochasticity plays a major role
in aging processes. There is enormous
variability in longevity traits among gene-
tically identical individuals across all spe-
cies tested. The causes of this stochastic-
ity and its role in aging and age-related
diseases remain poorly understood.
Numerous aging genes have been iden-
tified in nonvertebrates, which now
should be used to develop a systems-
level understanding of aging, including
both genetic and environmental influ-
ences. Studies should incorporate multi-
ple assessments of cellular and organ-
ismal function, including transcriptomics,
proteomics, and metabolomics, as well
as readouts of macromolecular damage
and activation of stress response path-
ways. Achieving a holistic view of aging
in organisms such as yeast, worms, and
flies will likely impact our understanding
of vertebrate aging, as did the identifica-
tion of single genes in those organisms.
It is also critical in mammals to assess
the relationship among genetics, environ-
ment, and drug interventions to predict
responses in human healthspan trials.712 Cell 159, November 6, 2014 ª2014 ElsevIntegrate Human Genetic
and Epigenetic Studies
with Animal Models
Human genome association studies
have identified aging-associated gene
variations from either genome-wide
unbiased or gene-targeted studies,
examining orthologs of animal aging
genes (Deelen et al., 2013). Working
between mouse and human genetics
will accelerate identification of human
aging genes and their mechanisms.
Strategies should include generating
orthologous or identical human mutant
alleles in mice, modeling rare variants
in genes from conserved longevity path-
ways.
The lack of validated molecular bio-
markers of human aging has impeded
progress. However, recent studies have
uncovered promising candidates that, if
validated, could be used to test interven-
tions. Epigenetic studies are among the
most exciting, with reports indicating
that human age can be predicted by
analyzing DNA methylation status. It
remains unclear whether these markers
forecast chronologic or biologic age,
which are likely distinct. If they indeed
measure biologic age, then a major hur-
dle to initiating human studies will be
overcome. Also, if similar DNA methyl-
ation sites are identified in mice, they
could be validated by determining
whether interventions such as rapamycin
delay the appearance of an aging pro-
file and whether chronic stressors accel-ier Inc.erate it. Other avenues to molecular
biomarkers, including metabolomic and
proteomic approaches, are also yielding
promising candidates and deserve equal
attention.
Compare and Contrast
Inflammation in Aging and Disease
Increasingly, inflammation is being linked
to aging and chronic disease (Salvioli
et al., 2013). Acute inflammatory re-
sponses to insults such as injury and
infection are critical for organismal
health and recovery. However, the basal
inflammatory response rises with age,
leading to low-level chronic inflammation
that is likely maladaptive, promoting
aging. There is a need to identify (1)
the pathways by which adaptive and
chronic inflammation are induced and
(2) the outcomes of ‘‘inflammaging.’’
Interventions designed to reduce chronic
inflammation while maintaining an effec-
tive adaptive response may have broad
benefits.
Senescent cells accumulate in multiple
tissues during aging and have a unique
senescence-associated secretory profile
(SASP) that includes many proinflamma-
tory cytokines (Coppe´ et al., 2008). Cell
senescence, whereby cells irreversibly
cease proliferation in response to stress,
was long suspected of driving organismal
aging. However, the number of senescent
cells in most aged tissues is limited. The
SASP potentially explains how a few
senescent cells can have broad, adverse
effects by secreting proinflammatory
factors with autocrine, paracrine, and
endocrine activities. It is important to
understand the in vivo consequences
of senescent cells and identify interven-
tional strategies that may mitigate their
effects. Recent genetic strategies to
ablate senescent cells in mice set the
stage for determining to what extent
they drive aspects of normal aging (Baker
et al., 2011).
Metabolic dysregulation accompanies
aging and is exacerbated by chronic dis-
eases such as type II diabetes. Among
the critical questions to be addressed
is how overnutrition and obesity affect
the aging metabolome, whether pro-
longevity interventions suppress age-
related metabolic dysfunction, and how
these interventions act in individuals with
type II diabetes. These issues are relevant
to inflammation as well, as adipose tissue
is a major source of inflammatory cyto-
kines. Determining how the proinflam-
matory response in adipose tissue is
initiated and propagated and the sys-
temic effects of this response on aging
should be a high priority. Links between
altered metabolism and inflammation
may underlie connections between aging
pathways previously thought to be inde-
pendent.
Develop New Animal Models of
Aging
Though yeast, worms, flies andmice have
been powerhouse aging models, there
are fundamental gaps in the knowledge
they provide. Understanding the diversity
of biological processes that can accel-
erate or protect against age-related
decline is critical and is best achieved by
investment in new model organisms that
accentuate other aspects of aging.
A major limitation in aging research is
the lack of primate and other vertebrate
models for preclinical testing. Primates,
often rhesus monkeys, are intermediate
between rodents and clinical trials in
humans. However, rhesus monkeys live
three to four decades, making aging
studies long and expensive. One solution
is to develop a second primate model—
the marmoset, whose lifespan is much
shorter. Other short-lived vertebrates
such as the African killifish may be useful
for the same reason: aging and disease
studies can be performed more rapidly
than current counterparts like zebrafish
and mice. Although human genetic data
on aging and age-related diseases is ex-
ploding, the speed of hypothesis testing
in current vertebrate models is lagging,
and a short-lived vertebrate may provide
a solution. Another model to consider is
dogs, which live in their owner’s environ-
ment, are well understood with regard to
aging and disease, and comprise a wide
range of pedigrees, providing genetic
diversity. Finding strategies to extend
healthspan in dogs may be an excellent
prelude to achieving the same goals in
humans.Exceptionally long-lived species also
offer promise. Though several species
such as clams are intriguing, the naked
mole rat has recently garnered interest.
These rodents are approximately the
same size as mice but reach 30 years of
age and are apparently devoid of cancer.
Comparative studies and genome
sequencing have suggested possible
mechanisms that underlie their extreme
longevity. One particularly informative
research path may be to engineer naked
mole rat longevity mechanisms into mice.
Conclusions
The goal of slowing aging has fascinated
humankind for millennia but has only
recently acquired credibility. Recent
findings that aging can be delayed in
mammals raise the possibility of prolong-
ing human healthspan. There is near
consensus among aging researchers
that this is possible, but only if resources
are available to accomplish goals in areas
ranging from basic biology to translational
medicine.
Here, we list a set of important areas of
future endeavor that aim to identify: (1) the
proximal causes of aging, (2) the mecha-
nisms by which aging enables disease,
and (3) a broad set of interventional
strategies for human testing. The current
approach to treating chronic diseases is
inadequate and fragmentary. By the time
chronic diseases are diagnosed, much
damage is done and undoing it is difficult.
Although understanding the unique fea-
tures of any given disease is laudatory
and is potentially of therapeutic value,
approaches to understand a common
cause, aging, will be uniquely important.
If we can understand how aging enables
disease, it may be possible (and even
easier) to target this common component
of disease. Targeting aging may allow
early intervention and damage avoidance,
maintaining vigor and activity while
offsetting the economic burdens of a
burgeoning aging population hampered
by multiple chronic diseases.Cell 159,ACKNOWLEDGMENTS
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